Moricizine bioavailability via simultaneous, dual, stable isotope administration: Bioequivalence implications

Jr Pieniaszek H.J., Michael Mayersohn, M. P. Adams, R. J. Reinhart, J. S. Barrett

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The relative bioavailability of a 200 mg film-coated tablet of [12C]moricizine·HCI in comparison to a 200 mg [13C6]moricizine·HCI oral solution was determined after simultaneous administration to 8 young healthy male subjects. Concentrations of [12C]moricizine·HCl and [13C6]moricizine·HCI were determined by thermospray liquid chromatography-mass spectrometry (LC-MS) using [2H11]moricizine·HCI as the internal standard. The mean absorption and disposition parameters of the tablet versus the solution were the following (% CV): maximum concentration, 0.83 (39%) versus 0.79 (39%) μg/mL; time of maximum concentration, 0.81 (40%) versus 0.65 (28%) hours; area under the concentration-time curve (AUC), 1.58 (39%) versus 1.49 (37%) μg·h/mL; apparent oral clearance, 150.7 (52%) versus 158.1 (50%) L/h; and t( 1/2 ), 1.9 (42%) versus 1.9 (42%) hours. The AUC for the tablet averaged 106% of the solution, which likely reflects a greater first-pass effect with the oral solution. Partitioning sources of variation confirmed the low (< 6%) intrasubject coefficient of variation (cv) afforded via the single-period, dual-isotope design. In contrast, a previous study using the conventional two-period crossover design determined the cvε about moricizine metrics to be in excess of 30%, resulting in classification of this drug as having highly variable absorption. The results of this studyfurther illustrate the benefits of dual, stable isotopes to assess bioavailability and bioequivalence. This paradigm results in a reduction in experimental time and subject inconvenience and lower costs in comparison with the standard crossover study. Perhaps most important is the improved statistical power for the evaluation of bioavailability or bioequivalence in the absence of period and sequence effects that confound the assessment of intrasubject variation in the standard crossover design. (C)1999 the American College of Clinical Pharmacology.

Original languageEnglish (US)
Pages (from-to)817-825
Number of pages9
JournalJournal of Clinical Pharmacology
Volume39
Issue number8
StatePublished - 1999
Externally publishedYes

Fingerprint

Moricizine
Therapeutic Equivalency
Isotopes
Biological Availability
Cross-Over Studies
Tablets
Liquid Chromatography
Mass Spectrometry
Healthy Volunteers
Costs and Cost Analysis
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Moricizine bioavailability via simultaneous, dual, stable isotope administration : Bioequivalence implications. / Pieniaszek H.J., Jr; Mayersohn, Michael; Adams, M. P.; Reinhart, R. J.; Barrett, J. S.

In: Journal of Clinical Pharmacology, Vol. 39, No. 8, 1999, p. 817-825.

Research output: Contribution to journalArticle

Pieniaszek H.J., Jr ; Mayersohn, Michael ; Adams, M. P. ; Reinhart, R. J. ; Barrett, J. S. / Moricizine bioavailability via simultaneous, dual, stable isotope administration : Bioequivalence implications. In: Journal of Clinical Pharmacology. 1999 ; Vol. 39, No. 8. pp. 817-825.
@article{e486e500a4f54c3f94e41bd14a878900,
title = "Moricizine bioavailability via simultaneous, dual, stable isotope administration: Bioequivalence implications",
abstract = "The relative bioavailability of a 200 mg film-coated tablet of [12C]moricizine·HCI in comparison to a 200 mg [13C6]moricizine·HCI oral solution was determined after simultaneous administration to 8 young healthy male subjects. Concentrations of [12C]moricizine·HCl and [13C6]moricizine·HCI were determined by thermospray liquid chromatography-mass spectrometry (LC-MS) using [2H11]moricizine·HCI as the internal standard. The mean absorption and disposition parameters of the tablet versus the solution were the following ({\%} CV): maximum concentration, 0.83 (39{\%}) versus 0.79 (39{\%}) μg/mL; time of maximum concentration, 0.81 (40{\%}) versus 0.65 (28{\%}) hours; area under the concentration-time curve (AUC), 1.58 (39{\%}) versus 1.49 (37{\%}) μg·h/mL; apparent oral clearance, 150.7 (52{\%}) versus 158.1 (50{\%}) L/h; and t( 1/2 ), 1.9 (42{\%}) versus 1.9 (42{\%}) hours. The AUC for the tablet averaged 106{\%} of the solution, which likely reflects a greater first-pass effect with the oral solution. Partitioning sources of variation confirmed the low (< 6{\%}) intrasubject coefficient of variation (cv) afforded via the single-period, dual-isotope design. In contrast, a previous study using the conventional two-period crossover design determined the cvε about moricizine metrics to be in excess of 30{\%}, resulting in classification of this drug as having highly variable absorption. The results of this studyfurther illustrate the benefits of dual, stable isotopes to assess bioavailability and bioequivalence. This paradigm results in a reduction in experimental time and subject inconvenience and lower costs in comparison with the standard crossover study. Perhaps most important is the improved statistical power for the evaluation of bioavailability or bioequivalence in the absence of period and sequence effects that confound the assessment of intrasubject variation in the standard crossover design. (C)1999 the American College of Clinical Pharmacology.",
author = "{Pieniaszek H.J.}, Jr and Michael Mayersohn and Adams, {M. P.} and Reinhart, {R. J.} and Barrett, {J. S.}",
year = "1999",
language = "English (US)",
volume = "39",
pages = "817--825",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "8",

}

TY - JOUR

T1 - Moricizine bioavailability via simultaneous, dual, stable isotope administration

T2 - Bioequivalence implications

AU - Pieniaszek H.J., Jr

AU - Mayersohn, Michael

AU - Adams, M. P.

AU - Reinhart, R. J.

AU - Barrett, J. S.

PY - 1999

Y1 - 1999

N2 - The relative bioavailability of a 200 mg film-coated tablet of [12C]moricizine·HCI in comparison to a 200 mg [13C6]moricizine·HCI oral solution was determined after simultaneous administration to 8 young healthy male subjects. Concentrations of [12C]moricizine·HCl and [13C6]moricizine·HCI were determined by thermospray liquid chromatography-mass spectrometry (LC-MS) using [2H11]moricizine·HCI as the internal standard. The mean absorption and disposition parameters of the tablet versus the solution were the following (% CV): maximum concentration, 0.83 (39%) versus 0.79 (39%) μg/mL; time of maximum concentration, 0.81 (40%) versus 0.65 (28%) hours; area under the concentration-time curve (AUC), 1.58 (39%) versus 1.49 (37%) μg·h/mL; apparent oral clearance, 150.7 (52%) versus 158.1 (50%) L/h; and t( 1/2 ), 1.9 (42%) versus 1.9 (42%) hours. The AUC for the tablet averaged 106% of the solution, which likely reflects a greater first-pass effect with the oral solution. Partitioning sources of variation confirmed the low (< 6%) intrasubject coefficient of variation (cv) afforded via the single-period, dual-isotope design. In contrast, a previous study using the conventional two-period crossover design determined the cvε about moricizine metrics to be in excess of 30%, resulting in classification of this drug as having highly variable absorption. The results of this studyfurther illustrate the benefits of dual, stable isotopes to assess bioavailability and bioequivalence. This paradigm results in a reduction in experimental time and subject inconvenience and lower costs in comparison with the standard crossover study. Perhaps most important is the improved statistical power for the evaluation of bioavailability or bioequivalence in the absence of period and sequence effects that confound the assessment of intrasubject variation in the standard crossover design. (C)1999 the American College of Clinical Pharmacology.

AB - The relative bioavailability of a 200 mg film-coated tablet of [12C]moricizine·HCI in comparison to a 200 mg [13C6]moricizine·HCI oral solution was determined after simultaneous administration to 8 young healthy male subjects. Concentrations of [12C]moricizine·HCl and [13C6]moricizine·HCI were determined by thermospray liquid chromatography-mass spectrometry (LC-MS) using [2H11]moricizine·HCI as the internal standard. The mean absorption and disposition parameters of the tablet versus the solution were the following (% CV): maximum concentration, 0.83 (39%) versus 0.79 (39%) μg/mL; time of maximum concentration, 0.81 (40%) versus 0.65 (28%) hours; area under the concentration-time curve (AUC), 1.58 (39%) versus 1.49 (37%) μg·h/mL; apparent oral clearance, 150.7 (52%) versus 158.1 (50%) L/h; and t( 1/2 ), 1.9 (42%) versus 1.9 (42%) hours. The AUC for the tablet averaged 106% of the solution, which likely reflects a greater first-pass effect with the oral solution. Partitioning sources of variation confirmed the low (< 6%) intrasubject coefficient of variation (cv) afforded via the single-period, dual-isotope design. In contrast, a previous study using the conventional two-period crossover design determined the cvε about moricizine metrics to be in excess of 30%, resulting in classification of this drug as having highly variable absorption. The results of this studyfurther illustrate the benefits of dual, stable isotopes to assess bioavailability and bioequivalence. This paradigm results in a reduction in experimental time and subject inconvenience and lower costs in comparison with the standard crossover study. Perhaps most important is the improved statistical power for the evaluation of bioavailability or bioequivalence in the absence of period and sequence effects that confound the assessment of intrasubject variation in the standard crossover design. (C)1999 the American College of Clinical Pharmacology.

UR - http://www.scopus.com/inward/record.url?scp=0033324606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033324606&partnerID=8YFLogxK

M3 - Article

C2 - 10434234

AN - SCOPUS:0033324606

VL - 39

SP - 817

EP - 825

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 8

ER -